FORMULATION, OPTIMIZATION AND EVALUATION OF OSIMERTINIB TABLETS

Article, Other literature type OPEN
Dr. K. Ramesh1*, Dr.M.Ganesh2, Dr. Suresh Kumar Packiriswamy3, G.Sridhar4;
(2019)

Osimertinib mesylate is a kinase inhibitor, prescribed for the treatment of patients, who are diagnosed with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC). The Innovator of the product is AstraZeneca and it... View more
Share - Bookmark

  • Download from
    ZENODO via ZENODO (Article, 2019)
  • Cite this publication